XLO on Nasdaq

Xilio Therapeutics, Inc.

American pharmaceutical preparations company, incorporated in Delaware. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with INTEGRATED BIOPHARMA INC, CUMBERLAND PHARMACEUTICALS INC or Aquestive Therapeutics, Inc., or pick any stock.

  • TickerXLO on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersWaltham, Massachusetts1
  • Incorporated inDE2
  • Business address828 Winter Street, Waltham, Ma 024512
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-95.9%Operating margin3
-80.1%Net margin3
589.9%Revenue growth, 20253
-99.3%Return on equity3
-$5.5MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$56.0M

Out of $43.8M in revenue.3 The company lost money this year.

Financial statements

Revenue3$43.8M in 2025+590% since 2024
0$20.0M$40.0M$60.0M2024: $6.3M$6.3M20242025: $43.8M$43.8M2025+590%
Operating income45673-$42.0M in 2025−23% since 2020
-$100.0M-$75.0M-$50.0M-$25.0M02020: -$54.6M-$54.6M20202021: -$75.0M-$75.0M2021+38%2022: -$89.1M-$89.1M2022+19%2023: -$79.1M-$79.1M2023−11%2024: -$60.6M-$60.6M2024−23%2025: -$42.0M-$42.0M2025−31%
Net income45673-$35.0M in 2025−37% since 2020
-$100.0M-$75.0M-$50.0M-$25.0M02020: -$55.2M-$55.2M20202021: -$75.8M-$75.8M2021+37%2022: -$88.2M-$88.2M2022+16%2023: -$76.4M-$76.4M2023−13%2024: -$58.2M-$58.2M2024−24%2025: -$35.0M-$35.0M2025−40%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
Total Revenue$43.8M$6.3M
Research and development$56.0M$41.2M
General and administrative$29.7M$24.8M
Restructuring$937.0K
Total operating expenses$85.7M$66.9M
Loss from operations-$42.0M-$60.6M
Change in fair value of common stock warrant liabilities$5.8M
Other income, net$1.1M$2.3M
Total other income, net$6.9M$2.3M
Net loss and comprehensive loss-$35.0M-$58.2M
Net loss per share, basic (in dollars per share)-$4.19-$15.24
Net loss per share, diluted (in dollars per share)-$4.19-$15.24
Weighted average common shares outstanding, basic (in shares)8.4M shares3.8M shares
Weighted average common shares outstanding, diluted (in shares)8.4M shares3.8M shares

Compare Xilio Therapeutics, Inc. with another company

Leadership

Who has led Xilio Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Rene Russo2021–now

President

  1. Martin H. Huber Jr.2021–2023
  2. Rene Russo2021–now

Chief financial officer

  1. Salvatore Giovine2021–2022
  2. Christopher James Frankenfield2025–now

Chief operating officer

  1. Christopher James Frankenfield2023–2024
2025
Board members and other officers (13)

Timeline

  1. Oct 21, 2021New chief executive Rene Russo becomes CEO11

Filings

349 filings to the SEC since October 2021: 6 annual reports, 17 quarterly reports, 65 major events, 150 insider forms, 47 large holders, 64 other. The latest 20:

  1. Oct 2, 20264 EDGAR
  2. Oct 2, 20263 EDGAR
  3. Aug 14, 2026SCHEDULE 13G/A EDGAR
  4. Aug 12, 2026S-8 EDGAR
  5. Aug 12, 202610-Q EDGAR
  6. Aug 12, 20268-K EDGAR
  7. Jun 12, 20264 EDGAR
  8. Jun 12, 20264 EDGAR
  9. Jun 12, 20264 EDGAR
  10. Jun 12, 20264 EDGAR
  11. Jun 12, 20264 EDGAR
  12. Jun 12, 20264 EDGAR
  13. Jun 12, 20264 EDGAR
  14. Jun 12, 20268-K EDGAR
  15. May 29, 2026EFFECT EDGAR
  16. May 27, 2026CORRESP EDGAR
  17. May 27, 2026S-3/A EDGAR
  18. May 18, 2026UPLOAD EDGAR
  19. May 15, 2026SCHEDULE 13G/A EDGAR
  20. May 15, 2026SCHEDULE 13G EDGAR

The 349 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

22 open-market trades by officers, directors and large owners since October 2021: 15 buys and 7 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 26, 2026Shannon James SamuelDirectorBuy5,000$8.79$44.0KForm 4
Jan 2, 2026Brennan Kevin M.SVP, FINANCE AND ACCOUNTINGSale1,826$0.64$1.2KForm 4
Jan 2, 2026Frankenfield Christopher JamesChief Financial OfficerSale7,030$0.64$4.5KForm 4
Jun 17, 2025Shannon James SamuelDirectorBuy25,000$0.69$17.2KForm 4
Jun 16, 2025Shannon James SamuelDirectorBuy45,000$0.69$31.1KForm 4
Jun 16, 2025Russo RenePRESIDENT AND CEOBuy36,289$0.68$24.7KForm 4
Jan 2, 2025Frankenfield Christopher JamesChief Financial OfficerSale6,954$0.98$6.8KForm 4
Jan 2, 2025Brennan Kevin M.SVP, FINANCE AND ACCOUNTINGSale1,803$0.98$1.8KForm 4
Dec 18, 2024GILEAD SCIENCES, INC.10% ownerBuy1,759,978$1.04$1.8MForm 4
Apr 2, 2024GILEAD SCIENCES, INC.10% ownerBuy485,250$0.76$368.8KForm 4
Feb 8, 2024Atlas Venture Fund XI, L.P.10% ownerSale1,000$0.64$640Form 4
Jan 12, 2024Atlas Venture Associates Opportunity I, L.P.10% ownerSale2,100$0.83$1.7KForm 4
Jan 11, 2024Atlas Venture Associates Opportunity I, L.P.10% ownerSale2,135$0.87$1.9KForm 4
Dec 10, 2021BCIP Life Sciences Associates, LP10% ownerBuy25,000$9.65$241.2KForm 4
Dec 9, 2021BCIP Life Sciences Associates, LP10% ownerBuy4,011$9.84$39.5KForm 4
Dec 8, 2021BCIP Life Sciences Associates, LP10% ownerBuy13,458$9.62$129.5KForm 4
Oct 26, 2021Deerfield Mgmt L.P.Buy775,000$16.00$12.4MForm 4
Oct 26, 2021Rock Springs Capital Master Fund LP10% ownerBuy500,000$16.00$8.0MForm 4
Oct 26, 2021BAY CITY CAPITAL LLC10% ownerBuy312,500$16.00$5.0MForm 4
Oct 26, 2021Atlas Venture Opportunity Fund I, L.P.10% ownerBuy187,500$16.00$3.0MForm 4

All 22 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Bain Capital Life Sciences Investors, LLC664,021$6.4M0.4%No change
Orbimed Advisors LLC592,300$5.7M0.1%New
Frazier Life Sciences Management, L.P.422,505$4.0M0.1%No change
Stonepine Capital Management, LLC225,994$2.2M1.6%+161,832
Vanguard Capital Management LLC178,517$1.7M0.0%+54,857
Sio Capital Management, LLC152,464$1.5M0.3%No change
Adage Capital Partners Gp, L.l.c.111,541$1.1M0.0%New
Merck & Co., Inc.105,982$1.0M0.2%No change
Renaissance Technologies LLC64,153$614.6K0.0%+14,587
Morgan Stanley56,954$545.6K0.0%−539
Geode Capital Management, LLC39,055$374.2K0.0%+1,858
Citadel Advisors LLC25,950$248.6K0.0%New
Vanguard Fiduciary Trust Co22,594$216.5K0.0%−5,881
Bridgeway Capital Management, LLC17,544$168.1K0.0%New
Two Sigma Investments, LP14,544$139.3K0.0%New
Velan Capital Investment Management LP14,285$136.8K0.1%No change
State Street Corp13,311$127.5K0.0%No change
Prelude Capital Management, LLC11,600$111.1K0.0%New
BlackRock, Inc.8,757$83.9K0.0%New
Steward Partners Investment Advisory, LLC714$6.8K0.0%New
Barclays PLC115$1.1K0.0%New
Key Financial Inc59$5650.0%No change
Jones Financial Companies Lllp29$2620.0%New
UBS Group AG14$1340.0%−4,024
Gsa Capital Partners Llp13,590$1300.0%−3,356

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45